Luis T. Campos

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations · Full text

Checkmate 063, Single-arm Trial, Medicine +8

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.

Richard Pazdur, Jaffer A. Ajani, Yehuda Z. Patt et al. · Journal of Clinical Oncology · 1990 · 140 citations

Immunology, Pathology, Phase Ii Study +18

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices

Vicki A. Morrison, Mitchell D. Wong, Dawn L. Hershman et al. · Journal of Managed Care Pharmacy · 2007 · 108 citations · Full text

Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer

Johanna C. Bendell, John Nemunaitis, S. Vukelja et al. · Journal of Clinical Oncology · 2011 · 105 citations · Full text

A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma

Devalingam Mahalingam, Julio Peguero, Putao Cen et al. · Cancers · 2019 · 89 citations · Full text